14th February, 2026

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – FDA inspection

Dear Sir / Madam,

This is to inform you that the US FDA conducted a general Good Manufacturing Practices (GMP) inspection of Piramal Pharma Limited's Digwal, Telangana, India facility from 9th February, 2026 to 13th February, 2026.

At the conclusion of the inspection, the US FDA issued a Form-483, with 4 observations. These observations are related to enhancement in procedures and not related to data integrity and are indicated to be classified as a VAI (voluntary action indicated). The Company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines.

The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

This is for your information and records.

Thank you,

Yours truly,
For **Piramal Pharma Limited**

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.02.14 12:50:00 +05'30'

Tanya Sanish
Company Secretary